Welcome to our dedicated page for Core Scientific SEC filings (Ticker: CORZR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Core Scientific's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Core Scientific's regulatory disclosures and financial reporting.
CORZ filing a Form 144 notice for the proposed sale of 140,000 shares of Common Stock, reported on 04/01/2026. The filing lists two underlying lots—59,388 shares from a merger/acquisition and 80,612 shares from Restricted Stock Units—that together equal the 140,000 shares.
The filing shows an aggregate amount of $2,094,400.00 and a reported shares outstanding figure of 315,332,655 as of 04/01/2026. The broker-dealer listed is Morgan Stanley Smith Barney LLC (Nasdaq). The notice documents an intended sale by an issuer-related source.
CORZ filing a Form 144 notice for the proposed sale of 140,000 shares of Common Stock, reported on 04/01/2026. The filing lists two underlying lots—59,388 shares from a merger/acquisition and 80,612 shares from Restricted Stock Units—that together equal the 140,000 shares.
The filing shows an aggregate amount of $2,094,400.00 and a reported shares outstanding figure of 315,332,655 as of 04/01/2026. The broker-dealer listed is Morgan Stanley Smith Barney LLC (Nasdaq). The notice documents an intended sale by an issuer-related source.
Core Scientific, Inc. outlines its 2025 shift toward high‑density colocation and AI/HPC infrastructure and seeks stockholder votes at its May 12, 2026 virtual annual meeting. The company expanded its CoreWeave agreement by 70 MW to about 590 MW of contracted capacity across five sites, with projected revenue of more than $10 billion over 12 years.
Across four locations, it advanced over 1 million square feet of data center shell, installed nearly $2 billion of infrastructure and supported more than 5 million labor hours, part of more than $5 billion of infrastructure investment largely expected to be funded by the customer. About 350 MW had been energized, with over 180 MW online and billing.
The proxy statement details three proposals: electing five directors, an advisory say‑on‑pay vote on named executive officer compensation, and ratification of KPMG as auditor. It also describes board independence, committee structure, a new cooperation agreement with Two Seas Capital on adding independent directors, and a revised executive pay program that increases performance‑based equity and links PSU vesting partly to relative total shareholder return.
Core Scientific, Inc. outlines its 2025 shift toward high‑density colocation and AI/HPC infrastructure and seeks stockholder votes at its May 12, 2026 virtual annual meeting. The company expanded its CoreWeave agreement by 70 MW to about 590 MW of contracted capacity across five sites, with projected revenue of more than $10 billion over 12 years.
Across four locations, it advanced over 1 million square feet of data center shell, installed nearly $2 billion of infrastructure and supported more than 5 million labor hours, part of more than $5 billion of infrastructure investment largely expected to be funded by the customer. About 350 MW had been energized, with over 180 MW online and billing.
The proxy statement details three proposals: electing five directors, an advisory say‑on‑pay vote on named executive officer compensation, and ratification of KPMG as auditor. It also describes board independence, committee structure, a new cooperation agreement with Two Seas Capital on adding independent directors, and a revised executive pay program that increases performance‑based equity and links PSU vesting partly to relative total shareholder return.
Core Scientific Inc — The Vanguard Group filed Amendment No. 3 to a Schedule 13G/A reporting 0 shares beneficially owned of Common Stock as of 03/13/2026. The filing explains an internal realignment on January 12, 2026 that disaggregated certain Vanguard subsidiaries' holdings from The Vanguard Group, Inc.
The reporting person certifies sole and shared voting and dispositive powers of 0 and states ownership is below 5%. The amendment is signed by Ashley Grim on 03/26/2026.
Core Scientific Inc — The Vanguard Group filed Amendment No. 3 to a Schedule 13G/A reporting 0 shares beneficially owned of Common Stock as of 03/13/2026. The filing explains an internal realignment on January 12, 2026 that disaggregated certain Vanguard subsidiaries' holdings from The Vanguard Group, Inc.
The reporting person certifies sole and shared voting and dispositive powers of 0 and states ownership is below 5%. The amendment is signed by Ashley Grim on 03/26/2026.
Core Scientific, Inc. expanded its short-term credit facility by an additional $500.0 million under an accordion feature, bringing total term loan commitments to $1.0 billion. The company borrowed the full incremental amount at a rate of SOFR plus 250 basis points.
Proceeds from this 364-day facility are expected to be used for general corporate purposes tied to developing data center assets, including equipment purchases, pre-development work, real estate acquisitions and energy procurement for high-density colocation and AI-focused infrastructure.
Core Scientific, Inc. expanded its short-term credit facility by an additional $500.0 million under an accordion feature, bringing total term loan commitments to $1.0 billion. The company borrowed the full incremental amount at a rate of SOFR plus 250 basis points.
Proceeds from this 364-day facility are expected to be used for general corporate purposes tied to developing data center assets, including equipment purchases, pre-development work, real estate acquisitions and energy procurement for high-density colocation and AI-focused infrastructure.
Core Scientific EVP and CFO James P. Nygaard Jr. reported a tax-related share disposition. On March 17, 2026, 92,725 shares of Common Stock were withheld at $16.42 per share to satisfy withholding tax obligations upon the vesting of restricted stock units, rather than sold in the open market.
After this withholding, Nygaard directly owns 928,928 shares of Core Scientific common stock. Footnotes indicate that a portion of his holdings also reflects earlier in-kind share distributions received for no cash consideration.
Core Scientific EVP and CFO James P. Nygaard Jr. reported a tax-related share disposition. On March 17, 2026, 92,725 shares of Common Stock were withheld at $16.42 per share to satisfy withholding tax obligations upon the vesting of restricted stock units, rather than sold in the open market.
After this withholding, Nygaard directly owns 928,928 shares of Core Scientific common stock. Footnotes indicate that a portion of his holdings also reflects earlier in-kind share distributions received for no cash consideration.
Valiant Capital Management reports passive stake in Core Scientific. Valiant Capital Management, L.P., Valiant Capital Management, LLC and Christopher R. Hansen jointly filed a Schedule 13G reporting beneficial ownership of 16,212,903 shares of Core Scientific, Inc. Common Stock, representing 5.1% of the class based on February 26, 2026.
The filing states the reporting persons have shared voting and shared dispositive power over the 16,212,903 shares. The Funds hold the shares for the benefit of their investors and no single Fund holds more than 5% of outstanding Common Stock.
Valiant Capital Management reports passive stake in Core Scientific. Valiant Capital Management, L.P., Valiant Capital Management, LLC and Christopher R. Hansen jointly filed a Schedule 13G reporting beneficial ownership of 16,212,903 shares of Core Scientific, Inc. Common Stock, representing 5.1% of the class based on February 26, 2026.
The filing states the reporting persons have shared voting and shared dispositive power over the 16,212,903 shares. The Funds hold the shares for the benefit of their investors and no single Fund holds more than 5% of outstanding Common Stock.
Core Scientific director Eric Stanton Weiss bought 7,000 shares of common stock in an open-market transaction at an average price of $14.5285 per share on March 9, 2026. After this purchase, he directly holds 252,262 shares of Core Scientific common stock.
Core Scientific director Eric Stanton Weiss bought 7,000 shares of common stock in an open-market transaction at an average price of $14.5285 per share on March 9, 2026. After this purchase, he directly holds 252,262 shares of Core Scientific common stock.
Core Scientific, Inc. entered into a senior secured term loan facility of $500.0 million with lenders arranged by Morgan Stanley Senior Funding, Inc. The 364-day facility bears interest at term SOFR plus 2.50%, and the company borrowed the full initial $500.0 million on March 5, 2026.
The credit agreement includes an accordion feature allowing Core Scientific to request up to an additional $500.0 million in commitments, for potential total commitments of $1.0 billion. Proceeds are earmarked for developing data center assets, including equipment, energy-related deposits and real estate, and to pay associated fees and expenses, but not to repay other debt or fund dividends.
The loans are guaranteed by certain wholly owned material domestic subsidiaries and secured by a first-priority lien on substantially all of their assets. Core Scientific may prepay at any time without penalty, but must also use 100% of specified asset sale, debt, insurance, equity raise and fee proceeds to reduce commitments or prepay loans, subject to customary exceptions.
Core Scientific, Inc. entered into a senior secured term loan facility of $500.0 million with lenders arranged by Morgan Stanley Senior Funding, Inc. The 364-day facility bears interest at term SOFR plus 2.50%, and the company borrowed the full initial $500.0 million on March 5, 2026.
The credit agreement includes an accordion feature allowing Core Scientific to request up to an additional $500.0 million in commitments, for potential total commitments of $1.0 billion. Proceeds are earmarked for developing data center assets, including equipment, energy-related deposits and real estate, and to pay associated fees and expenses, but not to repay other debt or fund dividends.
The loans are guaranteed by certain wholly owned material domestic subsidiaries and secured by a first-priority lien on substantially all of their assets. Core Scientific may prepay at any time without penalty, but must also use 100% of specified asset sale, debt, insurance, equity raise and fee proceeds to reduce commitments or prepay loans, subject to customary exceptions.
Core Scientific, Inc. (CORZ) received an amended Schedule 13D/A from Two Seas Capital and affiliates reporting a 5.9% beneficial stake in its common stock. The group reports beneficial ownership of 18,716,679 shares, including 313,646 shares issuable upon exercise of warrants and options to purchase 2,034,000 shares of common stock.
The stake is held across the Strategic Fund, the Global Fund and separate Accounts, with aggregate purchase prices of $36,028,987.73, $146,749,421.80 and $7,180,487.49, respectively. Two Seas Capital has sole voting and investment power under investment management agreements, while the underlying funds and accounts and their investors participate economically through their partnership or investment interests.
Core Scientific, Inc. (CORZ) received an amended Schedule 13D/A from Two Seas Capital and affiliates reporting a 5.9% beneficial stake in its common stock. The group reports beneficial ownership of 18,716,679 shares, including 313,646 shares issuable upon exercise of warrants and options to purchase 2,034,000 shares of common stock.
The stake is held across the Strategic Fund, the Global Fund and separate Accounts, with aggregate purchase prices of $36,028,987.73, $146,749,421.80 and $7,180,487.49, respectively. Two Seas Capital has sole voting and investment power under investment management agreements, while the underlying funds and accounts and their investors participate economically through their partnership or investment interests.
Core Scientific, Inc. files its Annual Report describing a major shift from bitcoin-focused operations to high-density colocation data centers for AI and other high-performance computing workloads. As of December 31, 2025, it owned or leased ten U.S. data centers with about 1.4 GW of gross utility power capacity and 920 MW of total leasable customer power capacity.
The company has three segments: Colocation, Digital Asset Self-Mining, and Digital Asset Hosted Mining, with most 2025 revenue still from bitcoin mining but expected to tilt toward colocation in 2026 through large contracts with CoreWeave. Core Scientific highlights heavy capital needs, power-cost and power-availability risks, bitcoin price and network hash-rate pressure, climate and regulatory uncertainty, and dependence on a single colocation customer.
It discloses a material weakness in internal control over financial reporting and ongoing remediation efforts. As of June 30, 2025, the aggregate market value of non-affiliate common stock was approximately $4.25 billion, and as of February 26, 2026, 315,332,655 common shares were outstanding.
Core Scientific, Inc. files its Annual Report describing a major shift from bitcoin-focused operations to high-density colocation data centers for AI and other high-performance computing workloads. As of December 31, 2025, it owned or leased ten U.S. data centers with about 1.4 GW of gross utility power capacity and 920 MW of total leasable customer power capacity.
The company has three segments: Colocation, Digital Asset Self-Mining, and Digital Asset Hosted Mining, with most 2025 revenue still from bitcoin mining but expected to tilt toward colocation in 2026 through large contracts with CoreWeave. Core Scientific highlights heavy capital needs, power-cost and power-availability risks, bitcoin price and network hash-rate pressure, climate and regulatory uncertainty, and dependence on a single colocation customer.
It discloses a material weakness in internal control over financial reporting and ongoing remediation efforts. As of June 30, 2025, the aggregate market value of non-affiliate common stock was approximately $4.25 billion, and as of February 26, 2026, 315,332,655 common shares were outstanding.